Phase I Safety and Pharmacokinetic Trials of 1263W94, a Novel Oral Anti-Human Cytomegalovirus Agent, in Healthy and Human Immunodeficiency Virus-Infected Subjects

類似資料

• Phase I Dose Escalation Trial Evaluating the Pharmacokinetics, Anti-Human Cytomegalovirus (HCMV) Activity, and Safety of 1263W94 in Human Immunodeficiency Virus-Infected Men with Asymptomatic HCMV Shedding
  著者:: Lalezari, Jacob P., 等
  出版事項: (2002)
• Interactions of 1263W94 with Other Antiviral Agents in Inhibition of Human Cytomegalovirus Replication
  著者:: Selleseth, Dean W., 等
  出版事項: (2003)
• Preclinical and Toxicology Studies of 1263W94, a Potent and Selective Inhibitor of Human Cytomegalovirus Replication
  著者:: Koszalka, George W., 等
  出版事項: (2002)
• Potent and Selective Inhibition of Human Cytomegalovirus Replication by 1263W94, a Benzimidazole l-Riboside with a Unique Mode of Action
  著者:: Biron, Karen K., 等
  出版事項: (2002)
• Inhibition of Ganciclovir-Susceptible and -Resistant Human Cytomegalovirus Clinical Isolates by the Benzimidazole l-Riboside 1263W94
  著者:: McSharry, James J., 等
  出版事項: (2001)